Paris-based biotech company Phagos has raised €25 million in a Series A funding round co-led by CapAgro, Hoxton Ventures, CapHorn and Demeter, with additional participation from Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital and Station F. The company, founded in 2021 by Alexandros Pantalis and Dr Adèle James, develops bacteriophage-based therapies, a natural alternative to antibiotics, and holds the first authorisation to market personalised phage-based veterinary treatments in the EU.